Open AccessOptogenetic Stimulation of Primary Cardiomyocytes Expressing ChR2
Author(s) -
Hoda Keshmiri Neghab,
Mohammad Hasan Soheilifar,
Ali Akbar Saboury,
Bahram Goliaei,
Jun Hong,
Gholamreza Esmaeeli Djavid
Publication year - 2021
Publication title -
journal of lasers in medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.443
H-Index - 21
eISSN - 2228-6721
pISSN - 2008-9783
DOI - 10.34172/jlms.2021.32
Subject(s) - optogenetics , medicine , stimulation , intracellular , electrophysiology , potassium channel , calcium in biology , channelrhodopsin , neuroscience , ion channel , cardiac electrophysiology , membrane potential , inward rectifier potassium ion channel , pharmacology , calcium , microbiology and biotechnology , biology , receptor
Non-clinical cardiovascular drug safety assessment is the main step in the progress of new pharmaceutical products. Cardiac drug safety testing focuses on a delayed rectifier potassium channel block and QT interval prolongation, whereas optogenetics is a powerful technology for modulating the electrophysiological properties of excitable cells. Methods: For this purpose, the blue light-gated ion channel, channelrhodopsin-2 (ChR2), has been introduced into isolated primary neonatal cardiomyocytes via a lentiviral vector. After being subjected to optical stimulation, transmembrane potential and intracellular calcium were assessed. Results: Here, we generated cardiomyocytes expressing ChR2 (light-sensitive protein), that upon optical stimulation, the cardiomyocytes depolarized result from alterations of membrane voltage and intracellular calcium. Conclusion: This cell model was easily adapted to a cell culture system in a laboratory, making this method very attractive for therapeutic research on cardiac optogenetics.